Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Jiang, Di Maria
Fallah-Rad, Nazanin
Lee, Roy
Ng, Pamela
Smith, Alan D.
Hansen, Aaron Richard
Joshua, Anthony M.
Sridhar, Srikala S.
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Princess Margaret Hosp, Toronto, ON, Canada
[5] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6550
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer
    Jiang, Di Maria
    Fallah-Rad, Nazanin
    Lee, Roy
    Ng, Pamela
    Smith, Alan D.
    Hansen, Aaron R.
    Joshua, Anthony M.
    Beca, Jaclyn
    Sridhar, Srikala S.
    EUROPEAN UROLOGY, 2021, 79 (02) : 177 - 179
  • [2] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [3] Refining the use of cabazitaxel in metastatic castrate-resistant prostate cancer
    Culine, Stephane
    EUROPEAN JOURNAL OF CANCER, 2018, 97 : 30 - 32
  • [4] AUSTRALIAN EXPERIENCE WITH CABAZITAXEL IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER (mCRPC)
    Ng, S.
    Gurney, H.
    Parente, P.
    Bahre, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 63 - 63
  • [5] Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
    Colbourn, Donald
    CASE REPORTS IN ONCOLOGY, 2012, 5 (02): : 320 - 324
  • [6] CABAZITAXEL IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC): AUSTRALIAN CLINICAL EXPERIENCE
    Gurney, H.
    Ng, S.
    Parente, P.
    Bahre, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 36 - 37
  • [7] PSA response and cabazitaxel outcomes stratified by prior docetaxel PSA response in metastatic castrate-resistant prostate cancer (mCRPC).
    Wee, Christopher Eing
    Nizam, Amanda
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Chen, Xiaoying
    Maroli, Kimberly
    Martin, Allison
    Bonham, Amanda
    Pietro, Carolyn
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 119 - 119
  • [8] Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?
    Mita, Alain C.
    Figlin, Robert
    Mita, Monica M.
    CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6574 - 6579
  • [9] Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).
    Kohli, Manish
    Huang, Xiaoyi
    Yuan, Tiezheng
    Sun, Zhifu
    Costello, Brian Addis
    Quevedo, Fernando
    Tan, Winston
    Nandy, Debashis
    Longenbach, Sherri
    Wang, Liang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
12345